Apceth Biopharma GmbH announced today that it has been selected to present at the European Hematology Society (EHA)-SWG Scientific Meeting that will take place in Amsterdam on November 23-25, 2017 on shaping the future of MSC therapy.
apceth’s presentation is titled “Mesenchymal stem cells genetically engineered to express alpha-1 anti-trypsin show superior efficacy in humanized graft-vs-host-disease model in comparison to native mesenchymal stem cells” and will be given by Dr. Felix Hermann, Head of Research and Development at apceth. Dr. Hermann will present the latest results regarding apceth-201 which is being developed for the treatment of graft-vs-host-disease (GvHD), as well as diabetes, inflammatory bowel disease, and COPD. The presentation will take place on Friday, November 24, 2017 between 16:00 – 17:00. We are looking forward to seeing you there.
About apceth Biopharma GmbH
apceth Biopharma is a leading company in cell-based gene therapeutics with an innovative portfolio of drug candidates for the treatment of chronic inflammation, autoimmunity (immunomodulation) and solid cancer (immuno-oncology). Through introduction of different therapeutic transgenes into Mesenchymal Stem Cells (MSCs), apceth is developing two potent next generation MSC-based gene therapy products. apceth-201 expresses the immunomodulatory protein Alpha-1 Antitrypsin for the treatment of graft-vs-host disease. The company’s second program, apceth-301, expresses a potent immunostimulatory “cocktail” of cytokines which locally activates the immune system to eradicate tumor cells. apceth-301 is currently being developed for glioblastoma.
apceth is also leading and certified Contract Development & Manufacturing Organization for Advanced Therapy Medicinal Products (ATMPs) with a broad international and transactlantic customer base. The company has state-of-the-art manufacturing facilities (ISO 5, ISO 7, ISO 8, BSL2 cleanrooms) and is certified according to regulatory requirements for ATMPs. apceth has successfully obtained multiple manufacturing licenses for different types of native and genetically engineered cells and cell-based products. apceth was the first company worldwide to obtain approval for the clinical testing of genetically engineered MSCs in patients. Irrespectively of the type of cells and cell products (native or genetically engineered HSCs, MSCs, and immune cells), or the cell source, apceth provides fully customized solutions in the development and production of every customer product
and process. Located centrally in the heart of Europe, apceth can perform efficient and fast supply of
the client’s products across the continent.
apceth Biopharma GmbH
Dr. Christine Guenther, CEO
Phone: +49 (0)89 7009608 0